Octreotide acetate

CAS 79517-01-4
Back to the Catalog Contact us about this API

General Information

Octreotide acetate is the current primary treatment for patients with acromegaly, together with other somatostatin analogue, Lanreotide.

About the API

Therapeutic category Endocrinology
Available formulations Injectables Injectables Long-Acting
Regulations EU DMF Flag EU DMF US DMF Flag US DMF

Related API products

Paricalcitol 131918-61-1 Cyproterone Acetate 427-51-0 Megestrol acetate 595-33-5 Ulipristal Acetate 126784-99-4

Make sure to check out our blog. Expert’s posts and community.
Browse Our Blog
Make sure to check out our blog. Expert’s posts and community.

The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources.

For more information on our services and products – including product suitability, intended uses and current availability – please contact Teva api Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes.

This site uses cookies (unless you have disabled them) to give you a better and personalized browsing experience and targeted ads.
By continuing your visit on this website, you agree to the use of Cookies on your device. Find out more in our Privacy Policy